💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vonoprazan

CHEMBL2079130 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
345.4 g/mol
LogP
2.0
Phase
4

Vonoprazan is a potassium-competitive acid blocker (PCAB) that reversibly blocks the gastric H+/K+-ATPase proton pump by competitively competing with potassium ions, producing potent and prolonged suppression of gastric acid secretion without requiring activation by acid. It is used for treatment of erosive esophagitis, gastroesophageal reflux disease, and H. pylori eradication regimens, demonstrating faster onset and more consistent acid suppression than proton pump inhibitors (PPIs). Its potassium-competitive mechanism is active regardless of meal timing.

आणविक भार

345.4000 g/mol

LogP

2.00

TPSA

72.40 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

उच्च रक्तचाप गैस्ट्रोइसोफेजियल रिफ्लक्स रोग लिम्फोमा

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H16FN3O2S

                    

                    
                    

                        
HBD / HBA

                        
1 / 5

                    

                    
                    

                        
घूर्णनीय बंधन

                        
5

                    

                    
                    
                    

                        
भारी परमाणु

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
Vonoprazan is a potassium-competitive acid blocker (PCAB) that reversibly blocks the gastric H+/K+-ATPase proton pump by competitively competing with potassium ions, producing potent and prolonged suppression of gastric acid secretion without requiring activation by acid. It is used for treatment of erosive esophagitis, gastroesophageal reflux disease, and H. pylori eradication regimens, demonstrating faster onset and more consistent acid suppression than proton pump inhibitors (PPIs). Its potassium-competitive mechanism is active regardless of meal timing.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Vonoprazan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2079130.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 15981397.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.